Mechanistic target of rapamycin kinase (mTOR) (mTOR)

The mechanistic target of rapamycin kinase (mTOR) is a critical serine/threonine protein kinase that functions as a central hub for regulating cellular metabolism, growth, and survival in response to environmental stimuli [1][2]. It integrates signals from nutrients, growth factors, and cellular energy levels to control key processes such as protein translation via p70S6 kinase and 4E-BP1, as well as the suppression of autophagy [3]. mTOR exists in two structurally and functionally distinct multiprotein complexes: mTORC1, which is sensitive to rapamycin and primarily controls growth, and mTORC2, which regulates cytoskeletal organization and AKT activation [1][4]. Dysregulation of the mTOR signaling pathway is a common driver in various human pathologies, particularly in oncology where overactivation promotes tumor progression, and in genetic disorders like Tuberous Sclerosis Complex [2][5]. Consequently, mTOR is a major therapeutic target; first-generation inhibitors (rapalogs) are widely used in transplant medicine and oncology, while second-generation ATP-competitive inhibitors are being developed to achieve more complete pathway blockade by targeting both mTOR complexes [4][6]. Sources: [1] UniProt: P42345 (MTOR_HUMAN) [2] Saxton, R. A., & Sabatini, D. M. (2017). mTOR Signaling in Growth, Metabolism, and Disease. Cell, 168(6), 960-976. [3] StatPearls: mTOR Inhibitors (2023). [4] Liu, G. Y., & Sabatini, D. M. (2020). mTOR at the center of node signaling to metabolic pathways. Nature Reviews Molecular Cell Biology, 21(4), 183-203. [5] PubMed: mTOR signaling in cancer (PMID: 31033483). [6] NIH: Clinical applications of mTOR inhibitors (NCBI Bookshelf).

Other names

Mammalian target of rapamycinFK506-binding protein 12-rapamycin complex-associated protein 1FKBP12-rapamycin complex-associated protein 1FRAPRAFT1RAPT1MTOR

Drugs targeting this protein typically function as allosteric inhibitors (rapalogs) that bind to FKBP12 to inhibit the mTORC1 complex, or as ATP-competitive inhibitors (TORKi) that directly target the catalytic site of the kinase to inhibit both mTORC1 and mTORC2 complexes.